UCB presents positive CIMZIA™ results from pivotal PHASE III Crohn's disease trial at major US medical meeting

October 31, 2005

Honolulu, Hawaii, October 31, 2005 - A single 400 mg injection of Cimzia™ (certolizumab pegol, CDP 870) every four weeks was effective in maintaining control of the signs and symptoms of Crohn's disease following induction therapy, according to pivotal phase III research presented this week at the annual meeting of the American College of Gastroenterology.

The study, entitled PRECiSE 2, found that a significantly higher proportion of patients who responded to an induction regimen of 400 mg Cimzia™ at weeks zero, two and six, were able to maintain clinical response and achieve remission by week 26 when given a single injection every four weeks, compared to those treated with placebo. A regulatory submission for the treatment of Crohn's disease is planned in the US during the first quarter of 2006.

"As there is considerable unmet need in the treatment of Crohn's disease, it is important that the research community continue to explore new therapies," said William J. Sandborn, MD, professor of medicine, Mayo Clinic College of Medicine, Rochester, MN, PRECiSE study investigator. "These data are exciting because it shows that Cimzia™ holds significant promise in meeting many of these needs."

Crohn's disease is a chronic inflammatory bowel disorder that affects approximately one million people in the US and Europe alone. , Because there is no cure, treatment is focused on suppressing the inflammatory response that is at the root of its cause. Cimzia™ is a biologic agent that has been designed to inhibit the production of tumor necrosis factor alpha (TNF- ), a protein involved in the inflammation process.

Study HighlightsThe PRECiSE clinical trial program is composed of four studies (PRECiSE 1, 2, 3 and 4). In addition to PRECiSE 2, the detailed results of which were presented at ACG, PRECiSE 1 is a 26-week double-blind, placebo-controlled trial, and represents the first long-term fully placebo-controlled clinical trial of a biologic in Crohn's disease. PRECiSE 1 successfully met its primary endpoints with statistical significance. As expected from a study with such a challenging trial design, top-line results were of lower magnitude than observed in the PRECiSE 2 trial. The detailed analysis of the PRECiSE 1 data is still ongoing, with results planned for presentation at a forthcoming gastroenterology congress. PRECiSE 3 and 4 are both 24-month, open-label trials for patients who participated in either PRECiSE 1 or 2, assessing the longer-term safety and tolerability of Cimzia™, and are currently ongoing.

The 26-week PRECiSE 2 study was designed to assess the safety and efficacy of Cimzia 400 mg for the maintenance of clinical response after open-label induction therapy in patients with mild to moderate Crohn's disease. Those who responded by week six were randomized to receive either a once-monthly maintenance dose of certolizumab 400 mg or placebo. Clinical response was defined as a 100 point drop in the Crohn's Disease Activity Index (CDAI), which measures the disease severity by taking into account a number of factors such as intensity of symptoms, medication and general well-being. The primary endpoint was the percentage of patients at week 26 with a C-reactive protein (CRP, a marker of inflammation) level > 10 mg who maintained a clinical response after successful induction. Major secondary endpoints included remission (CDAI < 150) in those with a CRP level > 10mg, and response and remission in the overall treatment population.

About Crohn's Disease
Crohn's disease is a chronic disorder that causes inflammation of the gastrointestinal tract, most commonly at the end of the small intestine (the ileum) and beginning of the large intestine (the colon). Common symptoms include diarrhea, fever, abdominal pain and weight loss. Although it can occur at any age, it primarily impacts young adults between the ages of 15 and 35. Because it is a chronic illness, patients experience an ongoing cycle of symptom "flare-ups" and periods of remission, when symptoms disappear or are controlled.1 This cycle can impact all aspects of a patient's life, including their pursuit of higher education and relationships with employers, friends and family members.

About Cimzia™
Cimzia™ is unique anti-TNF therapy in that it is a humanized antibody Fab' fragment chemically attached to polyethylene glycol (PEG, i.e. PEGylated). PEGylation increases the plasma half-life of certolizumab to approximately two weeks.

About UCB
UCB (www.ucb-group.com) is a global biopharmaceutical leader dedicated to the research, development and commercialization of innovative products in the fields of central nervous system disorders, allergy and respiratory diseases, immune and inflammatory disorders and oncology. UCB employs over 8,500 people operating in over 40 countries, and achieved revenues of € 2.1 billion (including net turnover, royalties, and fees) in 2004. UCB is listed on the Euronext Brussels with a market capitalization of approximately € 5.5 billion. Worldwide headquarters are located in Brussels, Belgium.

UCB Pharma, Inc. is the North American subsidiary of UCB, with U.S. headquarters located in Smyrna, Georgia. UCB's key products in the U.S. are Keppra® (levetiracetam), Zyrtec®† (cetirizine HCl), Tussionex® CIII (hydrocodone polistirex/chlorpheniramine polistirex), and Metadate CD™ CII (methylphenidate HCl, USP).

† Zyrtec is licensed to and co-promoted with Pfizer, Inc. in the United States.

For further information:
Lisa B. Garman Susan Thiele
Head, U.S. Communications & Public Relations Ketchum Public Relations
Mobile phone: +1 404.291.4772
Phone: +1 646.935.4133

For Investor Relations:
Jean-Christophe Donck
Vice President
Corporate Communication & Investor Relations
Phone +32.2.559.9588
Fax +32 2 559 9571
Email JC.Donck@UCB-Group.com
1. Crohn's and Colitis Foundation of America. Disease Information page: www.ccfa.org/info/about/crohns. Accessed October 3, 2005.
2. European Federation of Crohn's & Ulcerative Colitis Associations. Newsletter, pg. 30, May 2005 (www.efcca.org/efcca_nl22.pdf).
3. Crohn's and Colitis Foundation of America and the Digestive Disease National Coalition. Voices of Crohn's Survey: www.crohnsresource.com/voices/key_findings.html. Accessed September 22, 2005.

Ketchum UK

Related Placebo Articles from Brightsurf:

Effect of fluvoxamine vs placebo on clinical deterioration in outpatients with symptomatic COVID-19
This randomized trial compares the effects of fluvoxamine, a selective serotonin reuptake inhibitor with immunomodulatory effects, versus placebo on a composite of dyspnea or pneumonia and oxygen desaturation among adult outpatients with polymerase chain reaction-confirmed mild COVID-19 illness.

Hydroxychloroquine no more effective than placebo in preventing COVID-19
Clinical trial with COVID-19 testing of participants shows health care workers in contact with coronavirus patients who took hydroxychloroquine each day did not reduce their rate of infection.

Compared to placebo, vitamin D has no benefit for severe asthma attacks
Contrary to earlier observational results, vitamin D supplements do not prevent severe asthma attacks in at-risk children, according to the first placebo-controlled clinical trial to test this relationship.

UMN trial shows hydroxychloroquine has no benefit over placebo in preventing COVID-19
Today, University of Minnesota Medical School researchers published the results from the first randomized clinical trial testing hydroxychloroquine for the post-exposure prevention of COVID-19.

The placebo effect and psychedelic drugs: tripping on nothing?
A new study from McGill suggests that, in the right context, some people may experience psychedelic-like effects from placebos alone.

Methotrexate reduces joint damage progression over placebo in erosive hand OA
According to new research findings presented at the 2019 ACR/ARP Annual Meeting, methotrexate did not demonstrate superior efficacy over placebo for pain relief and function evolution at three and 12 months in patients with erosive hand osteoarthritis, but did significantly reduce the progression of joint damage over placebo and seems to facilitate bone remodeling in these patients.

Botulinum toxin reduces chronic migraine attacks, compared to placebo
A growing body of evidence supports the effectiveness of botulinum toxin injections in reducing the frequency of chronic migraine headaches, concludes an updated review and analysis in the January issue of Plastic and Reconstructive Surgery, the official medical journal of the American Society of Plastic Surgeons (ASPS).

Opioids vs. placebo, nonopioid alternatives for chronic noncancer pain
An estimated 50 million adults in the United States were living with chronic noncancer pain in 2016 and many of them were prescribed opioid medications, even though a clinical benefit is uncertain.

Probiotic no better than placebo for acute gastroenteritis in children
While probiotics are often used to treat acute gastroenteritis (also known as infectious diarrhea) in children, the latest evidence shows no significant differences in outcomes, compared to a placebo.

Most common shoulder operation is no more beneficial than placebo surgery
In a landmark study published this week in the BMJ, Finnish researchers show that one of the most common surgical procedures in the Western world is probably unnecessary.

Read More: Placebo News and Placebo Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.